BDBM526859 US11186577, Cmpd. No. 202A::US11186577, Cmpd. No. 202B

SMILES CC1N(Cc2cc(Cl)ccc2-n2c(nnc12)C1CC2(C1)CN(C2)c1ncccn1)C(=O)OC(CF)CF

InChI Key InChIKey=KXHBRROPICKYDV-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 526859   

TargetVasopressin V1a receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM526859(US11186577, Cmpd. No. 202B | US11186577, Cmpd. No....)
Affinity DataIC50: 100nMAssay Description:The purpose of this assay was to determine the inhibitory effect of synthesized compounds on the Vasopressin V1a receptor. The assay as performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetVasopressin V1b receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM526859(US11186577, Cmpd. No. 202B | US11186577, Cmpd. No....)
Affinity DataIC50: 1.00E+3nMAssay Description:The purpose of the assay is to determine the inhibitory effect of synthesized compounds on the Vasopressin V1b receptor. The assay was performed in C...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetOxytocin receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM526859(US11186577, Cmpd. No. 202B | US11186577, Cmpd. No....)
Affinity DataIC50: 1.00E+3nMAssay Description:This assay was performed in CHEM-1 cells expressing the human Oxytocin Receptor (hOTR) to determine the inhibitory effect of the compounds of the inv...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetVasopressin V2 receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM526859(US11186577, Cmpd. No. 202B | US11186577, Cmpd. No....)
Affinity DataIC50: 1.00E+3nMAssay Description:The purpose of the assay was to determine the inhibitory effect of synthesized compounds on the Vasopressin receptor 2. The assay was performed in co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetOxytocin receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM526859(US11186577, Cmpd. No. 202B | US11186577, Cmpd. No....)
Affinity DataIC50: 1.00E+3nMAssay Description:This assay was performed in CHEM-1 cells expressing the human Oxytocin Receptor (hOTR) to determine the inhibitory effect of the compounds of the inv...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetVasopressin V1a receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM526859(US11186577, Cmpd. No. 202B | US11186577, Cmpd. No....)
Affinity DataIC50: 1.00E+3nMAssay Description:The purpose of this assay was to determine the inhibitory effect of synthesized compounds on the Vasopressin V1a receptor. The assay as performed in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent